Pharvaris (PHVS) Competitors

Pharvaris (NASDAQ:PHVS) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Does the media favor PHVS or SWTX?

In the previous week, Pharvaris had 12 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 22 mentions for Pharvaris and 10 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 1.55 beat Pharvaris' score of 0.33 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
SpringWorks Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is PHVS or SWTX more profitable?

Pharvaris has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -134.73%. Pharvaris' return on equity of -38.52% beat SpringWorks Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-38.52%	-36.69%
SpringWorks Therapeutics	-134.73%	-46.74%	-41.12%

Do analysts recommend PHVS or SWTX?

Pharvaris presently has a consensus price target of $40.67, indicating a potential upside of 142.21%. SpringWorks Therapeutics has a consensus price target of $52.57, indicating a potential upside of 13.56%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts clearly believe Pharvaris is more favorable than SpringWorks Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
SpringWorks Therapeutics	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.13

Which has more volatility & risk, PHVS or SWTX?

Pharvaris has a beta of -2.85, meaning that its share price is 385% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Does the MarketBeat Community believe in PHVS or SWTX?

SpringWorks Therapeutics received 68 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 67.95% of users gave SpringWorks Therapeutics an outperform vote while only 67.86% of users gave Pharvaris an outperform vote.

Company	Underperform	Outperform
Pharvaris	Outperform Votes 38 67.86%	Underperform Votes 18 32.14%
SpringWorks Therapeutics	Outperform Votes 106 67.95%	Underperform Votes 50 32.05%

Which has stronger valuation & earnings, PHVS or SWTX?

Pharvaris has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$109.18M	-$3.01	-5.58
SpringWorks Therapeutics	$219.67M	15.87	-$325.10M	-$3.41	-13.58

Summary

Pharvaris beats SpringWorks Therapeutics on 10 of the 15 factors compared between the two stocks.